Amid the continuing challenges that infectious diseases pose to preventive healthcare systems, Naviva Group organized a nationwide series of scientific conferences and professional forums on varicella prevention across multiple provinces and cities. Conducted in a hybrid format combining in-person and online sessions, the program aimed to provide in-depth updates on varicella prevention and to share advancements in the application of the MAV/06 vaccine strain in preventive medical practice.
Photo: Scientific Conference Hosted at Mekong Hospital
With a strategic focus on proactive disease prevention
Varicella is a contagious disease that tends to increase during seasonal transitions and often surges in the early months of the year, particularly when children gather and study in crowded environments. According to data from the Pasteur Institute in Ho Chi Minh city, 90% of reported cases occur among children aged 2 to 7 [1]. The disease spreads rapidly and carries the risk of serious complications if not properly prevented and monitored.
Photo: Naviva Nam Hung Viet personnels
In recent years, preventive healthcare has increasingly been recognized as a central pillar in strategies to safeguard public health. Amid the evolving and complex landscape of infectious diseases, the timely update of scientific evidence, professional guidelines, and immunization protocols is considered a critical factor in enhancing the effectiveness of disease prevention and enabling healthcare professionals to meet the growing demands of community health services.
Scientific Updates on the MAV/06 Strain
At the conference, Dr. Le Thi Hai Yen – Head of Training and Quality Control at Naviva Group, delivered a presentation entitled “Advancements in Varicella Prevention Using the MAV/06 Strain.” The report provided an in-depth analysis of the development history and real-world application of this viral strain, which has been implemented in South Korea since 1993 and incorporated into the country’s National Immunization Program.
Photo: Dr. Le Thi Hai Yen – Head of Training and Quality Control at Naviva Group
According to Dr. Yen, the first-generation varicella vaccine derived from the MAV/06 strain has been licensed in more than 30 countries with over 30 million doses administered worldwide, and has been deployed in Vietnam since 2008. Post-marketing surveillance data have demonstrated sustained protective efficacy and a favorable safety profile, providing a strong scientific foundation for the continued research and development of next-generation, improved vaccine formulations.
Photo: Scientific Conference Hosted at Nhi Dong Hospital 1
Building upon this foundation, the second-generation varicella vaccine derived from the MAV/06 strain has been technologically upgraded, incorporating the MRC-5 cell line in accordance with recommendations from the World Health Organization. Its fully automated, closed manufacturing process, free from antibiotic components, delivers a highly stable vaccine formulation that meets current standards for quality and safety in immunization practice.
Varicella Immunization in Line with the Latest WHO Recommendations
Advancing from the first-generation MAV/06 platform with significant enhancements, the second-generation MAV/06 varicella vaccine fulfills the quality and safety standards set by the World Health Organization and has obtained WHO prequalification (WHO PQ). The product has been confirmed to demonstrate a safety profile and immunogenicity comparable to currently circulating Oka strain–based vaccines, and the second-generation MAV/06 vaccine is now exclusively distributed in Vietnam.
Photo: The scientific session was conducted in an online format, attracting the active participation of a large number of healthcare professionals.
In its latest recommendations, the World Health Organization advises a two-dose schedule to achieve optimal protection against varicella, demonstrating significantly higher protective efficacy compared to a single-dose regimen.
At the same time, the World Health Organization also acknowledges that interchangeability between live attenuated varicella vaccines derived from the Oka strain and the MAV/06 strain is safe, with no adverse reactions reported in healthy vaccinated children.
Photo: Scientific Conference Hosted at An Sinh Hospital
Partnering for a Healthier Community
In Vietnam, Naviva Group is the authorized distributor of the second-generation MAV/06 varicella vaccine – BARYCELA inj., working alongside healthcare facilities to enhance the quality and effectiveness of immunization services nationwide.
By supplying vaccines that meet international standards, the company helps strengthen immunization system capacity, particularly in varicella prevention, thereby contributing to improved preventive healthcare outcomes and the protection of public health.
Through its scientific conference, Naviva Group reaffirms its role as a vital bridge between international vaccine manufacturers and the domestic healthcare system, supporting healthcare professionals in updating their knowledge, advancing immunization practices, and reinforcing the effectiveness of varicella prevention efforts.
Photo: Scientific Conference on “Advancements in Varicella Prevention with the MAV/06 Strain” in Da Nang
| BARYCELA Inj., a next-generation varicella vaccine developed by GC Biopharma from the MAV/06 strain, demonstrates immunogenicity and safety comparable to Oka strain–based vaccines and can be administered according to the current two-dose schedule [10].
Recommended Two-Dose Schedule for Optimal Immunity Children 12 months to 12 years of age: – Dose 1: From 12 months of age – Dose 2: At least 3 months after the first dose, or as a booster at 4 to 6 years of age In Vietnam, NAVIVA GROUP is the authorized distributor of the second-generation MAV/06 varicella vaccine under the brand name BARYCELA Inj. (GC Biopharma – South Korea). With more than 21 years of experience in vaccines and biological medical products, NAVIVA GROUP collaborates closely with healthcare facilities to enhance community access to safe, effective, and high-quality vaccines. The company is committed to ensuring a stable supply chain and strict compliance with GSP/GDP standards in storage and distribution, while actively supporting initiatives that promote awareness of proactive and safe immunization. 📞 Hotline: 0905 584 666
|
References:
